Penile cancer: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Muneer(University College London Hospitals NHS Foundation Trust), Tom Powles(Queen Mary University of London), Gert De Meerleer(KU Leuven), Jourik A. Gietema(University Medical Center Groningen), Karim Fizazi(Université de Lille), Éva Compérat(Vienna General Hospital), Alex Kirkham, Marco Bandini(IRCCS Ospedale San Raffaele), Vijay Sangar(The Christie NHS Foundation Trust), Constantine Alifrangis(University College London Hospitals NHS Foundation Trust), Silke Gillessen(Institute of Oncology Research)
ESMO Open
July 1, 2024
10.1016/j.esmoop.2024.103481
Cited by 36

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k